DEVICE-SUPPORTED VS ROUTINE (INVESTIGATOR-RECOMMENDED) TITRATION OF INSULIN GLARGINE 300 U/ML (GLA-300) IN TYPE 2 DIABETES (T2DM): EFFICACY AND TREATMENT SATISFACTION

被引：0
|
作者：
Flacke, F. [1 ]
Edelman, S. [2 ]
Bain, S. [3 ]
Hasslacher, C. [4 ]
Vespasiani, G. [5 ]
Goyeau, H. [6 ]
Woloschak, M. [7 ]
Davies, M. [8 ]
机构：
[1] Sanofi, Global Diabet Div, Franfurt, Germany
[2] Univ Calif San Diego, Vet Affairs Med Ctr, San Diego, CA 92161 USA
[3] Swansea Univ, Sch Med, Inst Life Sci, Coll Med, Swansea, W Glam, Wales
[4] Diabet Inst Heidelberg, Clin Studies, Heidelberg, Germany
[5] Ctr Outcomes Res & Clin Epidemiol, CORESEARCH, Pescara, Italy
[6] Sanofi, Res & Dev, Chilly Mazarin, France
[7] Sanofi, Diabet, New York, NY USA
[8] Univ Leicester, Univ Hosp Leicester, Diabet Res Ctr, Leicester, Leics, England
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
063
引用
收藏
页码：A30 / A31
页数：2
相关论文
共 50 条
  • [1] Device-Supported vs. Routine Titration of Insulin Glargine 300 U/mL (Gla-300) in T2DM: Efficacy and Safety
    Edelman, Steven
    Bain, Steve
    Hasslacher, Christoph
    Charpentier, Guillaume
    Vespasiani, Giacomo
    Flacke, Frank
    Goyeau, Harmonie
    Woloschak, Michael
    Davies, Melanie
    DIABETES, 2017, 66 : LB34 - LB34
  • [2] Device-supported vs routine titration of insulin glargine 300 U/ml (Gla-300) in type 2 diabetes: efficacy and safety
    Flacke, F.
    Edelman, S.
    Bain, S.
    Hasslacher, C.
    Charpentier, G.
    Vespasiani, G.
    Goyeau, H.
    Woloschak, M.
    Davies, M.
    DIABETOLOGIA, 2017, 60 : S307 - S307
  • [3] INSULIN GLARGINE 300 U/ML (GLA-300) VS 100 U/ML (GLA-100) IN OLDER PEOPLE WITH T2DM: RESULTS FROM A RANDOMIZED TRIAL
    Ritzel, R.
    Espinasse, M.
    Muehlen-Bartmer, I.
    Zhang, N.
    Munshi, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A135 - A136
  • [4] Insulin Glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) in older people with T2Dm: Results from a randomized trial
    Ritzel, Robert
    Vonbank, Alexander
    Espinasse, Melanie
    Muehlen-Bartmer, Ingrid
    Zhang, Nue
    Munshi, Medha
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 369 - 369
  • [5] A CLINICALLY DEFINED NOCTURNAL WINDOW FOR ANALYSIS OF HYPOGLYCEMIA: NEW INSULIN GLARGINE 300U/ML (GLA-300) IN TYPE 2 DIABETES (T2DM)
    Riddle, M. C.
    Home, P. D.
    Avogaro, A.
    Gimenez Alvarez, M.
    Merino-Trigo, A.
    Grisoni, M. L.
    Glezer, S.
    Bolli, G. B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A45 - A46
  • [6] Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes Mellitus (T2DM) Uncontrolled on Basal Insulins (BI): ARTEMIS-DM Study
    Sethi, Bipin
    Alrubeaan, Khalid
    Unubol, Mustafa
    Mabunay, Maria Aileen N.
    Naqvi, Mubarak
    Berthou, Baptiste
    Pilorget, Valerie
    Frechtel, Gustavo
    DIABETES, 2021, 70
  • [7] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [8] EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES (T2DM): A SUB ANALYSIS OF ATOS STUDY
    Khan, N.
    Al Shaikh, A. R.
    Hassoun, A.
    Mabunay, M. A. N.
    Magdy, A.
    Salah, M.
    Al Abdella, N.
    Safarini, S.
    Al Dahi, W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A102 - A103
  • [9] BUDGET IMPACT ANALYSIS OF INSULIN GLARGINE-300U/ML (GLA-300) FOR TREATMENT OF T1DM AND T2DM IN ALGERIAN SETTING
    Azzoug, S.
    Levy, P.
    Aissaoui, A.
    Hachelaf, Z.
    VALUE IN HEALTH, 2022, 25 (12) : S121 - S121
  • [10] INSULIN GLARGINE 300 U/ML (GLA-300) VS 100 U/ML (GLA-100) IN PEOPLE ≥75 YEARS OLD WITH T2DM: SECONDARY ANALYSIS OF THE SENIOR STUDY
    Harris, S.
    Ritzel, R.
    Roussel, R.
    Baron, H.
    Florez, H.
    Espinasse, M.
    Muehlen-Bartmer, I.
    Zhang, N.
    Munshi, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A136 - A136
12345